Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 22Lung Neoplasms 11Brain Neoplasms 4Rare Tumor 1Radiation Pneumonitis 1Non-small Cell Lung Cancer Metastatic 1Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor 1Meningeal Carcinomatosis 1Liver Diseases 1EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor 1Digestive System Diseases 1Carcinoma 1Aumolertinib 1Advanced Non-small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

Pemetrexed 2rofecoxib 1pembrolizumab 1paclitaxel poliglumex 1osimertinib 1aumolertinib 1atezolizumab 1anlotinib 1Radiosurgery 1RO5126766 1Nivolumab 1Gemcitabine 1Drug Therapy 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Non-small Cell Lung Cancer × aumolertinib × Clear all
NCT06043973 2023-09-21

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Qianfoshan Hospital

Phase 3 Recruiting
98 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡